Advertisement


Steven M. Horwitz, MD, on PTCL: Update on Efficacy of Duvelisib Dose Optimization

2020 ASH Annual Meeting & Exposition

Advertisement

Steven M. Horwitz, MD, of Memorial Sloan Kettering Cancer Center, discusses phase II data from the Primo trial, which support continued evaluation of duvelisib as a treatment option for relapsed or refractory peripheral T-cell lymphoma due to consistent response rates (Abstract 44).



Related Videos

Hematologic Malignancies
Lymphoma
Multiple Myeloma
Issues in Oncology
Palliative Care

Lena E. Winestone, MD, MSHP, on Health-Care Disparities in Hematologic Cancers: Real-World Data

Lena E. Winestone, MD, MSHP, of the University of California, San Francisco and Benioff Children’s Hospital, reviews different aspects of bias in treatment delivery, including patient selection for clinical trials; racial and ethnic disparities in survival for indolent non-Hodgkin diffuse large B-cell lymphomas; and end-of-life hospitalization of patients with multiple myeloma, as well as outcome disparities (Abstracts 207-212).

Lymphoma
Immunotherapy

Andrew D. Zelenetz, MD, PhD, on Mantle Cell Lymphoma: Immunochemotherapy Plus Lenalidomide

Andrew D. Zelenetz, MD, PhD, of Memorial Sloan Kettering Cancer Center, discusses phase II results from a single-center study that explored a novel approach for high-risk patients with mantle cell lymphoma. Among patients with TP53 wild-type disease, the data suggested this treatment was effective (Abstract 119).

Lymphoma
Immunotherapy

Caron A. Jacobson, MD, on Treating Large B-Cell Lymphoma With Axicabtagene Ciloleucel

Caron A. Jacobson, MD, of the Dana-Farber Cancer Institute, discusses results from the ZUMA-9 C2 study, an ongoing trial that is exploring axicabtagene ciloleucel in patients with relapsed or refractory large B-cell lymphoma (Abstract 2100).

Leukemia
Lymphoma

David T. Teachey, MD, on Pediatric Leukemia and Lymphoma: New Findings on Cranial Radiation and Bortezomib

David T. Teachey, MD, of the University of Pennsylvania and Children’s Hospital of Philadelphia, discusses data showing that cranial radiation might be eliminated in most children with T-cell acute lymphoblastic leukemia and that bortezomib may improve survival in children with T-cell lymphoblastic lymphoma (Abstract 266).

Issues in Oncology
Leukemia

Ann-Kathrin Eisfeld, MD, on AML in Black Patients: Racial Disparities in Survival Outcomes

Ann-Kathrin Eisfeld, MD, of The Ohio State University Comprehensive Cancer Center, discusses SEER data showing that patients with acute myeloid leukemia who are Black and younger than age 60 may have poor survival outcomes, a disparity that should be addressed and further studied to establish molecular risk profiles (Abstract 6).

Advertisement

Advertisement



Advertisement